MDWD - MediWound Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.4100
+0.2400 (+7.57%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.1700
Open3.1900
Bid0.0000 x 1300
Ask0.0000 x 1000
Day's Range3.1600 - 3.5100
52 Week Range3.0000 - 6.7500
Volume105,741
Avg. Volume76,037
Market Cap92.68M
Beta (3Y Monthly)1.00
PE Ratio (TTM)N/A
EPS (TTM)-0.0240
Earnings DateJul 28, 2017 - Jul 31, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    MediWound to Host Analyst Day on its Innovative Product EscharEx® for Debridement of Chronic Wounds

    MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, will host an analyst day on its innovative product for chronic wounds on Monday, July 22nd at 12:00pm EDT in New York City. The meeting will feature a presentation by key opinion leader (KOL) John Lantis, MD, Mount Sinai West, St. Luke’s Roosevelt Hospitals, and the Icahn School of Medicine, who will discuss the current treatment landscape as well as the unmet medical need for treating patients with chronic wounds.

  • Does The MediWound Ltd. (NASDAQ:MDWD) Share Price Tend To Follow The Market?
    Simply Wall St.28 days ago

    Does The MediWound Ltd. (NASDAQ:MDWD) Share Price Tend To Follow The Market?

    Anyone researching MediWound Ltd. (NASDAQ:MDWD) might want to consider the historical volatility of the share price...

  • How Does MediWound Ltd. (NASDAQ:MDWD) Affect Your Portfolio Volatility?
    Simply Wall St.28 days ago

    How Does MediWound Ltd. (NASDAQ:MDWD) Affect Your Portfolio Volatility?

    If you own shares in MediWound Ltd. (NASDAQ:MDWD) then it's worth thinking about how it contributes to the volatility...

  • Thomson Reuters StreetEventslast month

    Edited Transcript of MDWD earnings conference call or presentation 21-May-19 12:30pm GMT

    Q1 2019 Mediwound Ltd Earnings Call

  • GlobeNewswirelast month

    MediWound Appoints Mr. Boaz Gur-Lavie as Chief Financial Officer

    MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the appointment of Mr. Boaz Gur-Lavie as Chief Financial Officer, effective June 11, 2019. “We are pleased to have Boaz, a skilled and experienced financial management executive, join our dedicated and experienced leadership team,” said Sharon Malka, Chief Executive Officer of MediWound.

  • GlobeNewswirelast month

    NexoBrid® Receives Marketing Authorization from Peru’s Ministry of Health

    MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced receipt of authorization from the Ministry of Health in Peru to market and distribute NexoBrid for the removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns.  Avalon Pharmaceutical Peru S.A.C, MediWound’s exclusive distribution partner in Peru, received the marketing authorization and intends to launch NexoBrid in Peru in the first half of 2020.

  • GlobeNewswire2 months ago

    BARDA Upsizes Support for NexoBrid with an Additional $21 Million to Fund Continuous Access Treatment Protocol for Thermal Burn

    MediWound to initiate NexoBrid expanded access treatment protocol (NEXT) in the third quarter of 2019, allowing for ongoing use of NexoBrid to treat burn patients in U.S. YAVNE, Israel, May 29, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) has upsized its awarded contract with MediWound and provided supplemental funding of $21 million to initiate NexoBrid expanded access treatment protocol (NEXT). Under the modified contract including this supplemental amount, BARDA will provide technical assistance and a total amount of $77 million in funding for NexoBrid development activities towards U.S. marketing approval from the Food and Drug Administration (FDA).

  • MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
    Zacks2 months ago

    MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates

    MediWound (MDWD) delivered earnings and revenue surprises of -7.14% and -23.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    MediWound: 1Q Earnings Snapshot

    The Yavne, Israel-based company said it had a loss of 15 cents per share. The developer of treatments for burns and hard-to-heal wounds posted revenue of $461,000 in the period. The company's shares closed ...

  • GlobeNewswire2 months ago

    MediWound Reports First Quarter 2019 Financial Results

    Met Primary and All Secondary Endpoints in Pivotal Phase 3 DETECT Study; NexoBrid BLA Filing Planned for Fourth Quarter of 2019 Signed Exclusive License Agreement with Vericel.

  • GlobeNewswire2 months ago

    MediWound to Host First Quarter Financial Results Conference Call on May 21at 8:30 a.m. Eastern Time

    MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the first quarter ended March 31, 2019 at 8:30 am Eastern Time on Tuesday, May 21, 2019. Following the release, MediWound's management will host a conference call for the investment community beginning at 8:30 a.m. Eastern Time to discuss the financial results and to answer questions.

  • Vericel (VCEL) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Vericel (VCEL) Q1 2019 Earnings Call Transcript

    VCEL earnings call for the period ending March 31, 2019.

  • GlobeNewswire2 months ago

    MediWound Enters into Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid® in North America

    MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it has entered into exclusive license and supply agreements with Vericel Corporation (VCEL) to commercialize NexoBrid® in North America (NA). NexoBrid is a topically-administered biologic product that removes eschar in patients with deep partial and full-thickness thermal burns, which is approved in the European Union and other international markets. The pivotal U.S. phase 3 DETECT clinical study met its primary and all secondary endpoints, and the submission of the Biological License Application (BLA) to the U.S. Food and Drug Administration (FDA) is planned for the fourth quarter of 2019.

  • Will MediWound (MDWD) Report Negative Q1 Earnings? What You Should Know
    Zacks3 months ago

    Will MediWound (MDWD) Report Negative Q1 Earnings? What You Should Know

    MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of MDWD earnings conference call or presentation 25-Mar-19 12:30pm GMT

    Q4 2018 Mediwound Ltd Earnings Call

  • GlobeNewswire4 months ago

    MediWound Files Annual Report on Form 20-F for the Year Ended December 31, 2018

    MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2018 with the U.S. Securities and Exchange Commission (the “SEC”). The annual report on Form 20-F, which contains MediWound’s audited financial statements, can be accessed on the SEC’s website at http://www.sec.gov, as well as via the Company’s investor relations website at http://ir.mediwound.com/investor-relations. The Company will deliver a hard copy of its annual report on Form 20-F, including its complete audited financial statements, free of charge, to its shareholders upon request to Jeremy Feffer, Managing Director, LifeSci Advisors, at jeremy@lifesciadvisors.com.

  • Associated Press4 months ago

    MediWound: 4Q Earnings Snapshot

    The Yavne, Israel-based company said it had profit of 39 cents per share. Losses, adjusted for non-recurring gains and to account for discontinued operations, were 6 cents per share. The results surpassed ...

  • GlobeNewswire4 months ago

    MediWound Reports Fourth Quarter and Fiscal Year 2018 Financial Results

    Met Primary and All Secondary Endpoints in its Pivotal Phase 3 Study (DETECT) in NexoBrid® for Eschar Removal of Severe Thermal Burns Awarded Additional BARDA Contract Valued.

  • GlobeNewswire4 months ago

    MediWound to Host Fourth Quarter & Fiscal 2018 Financial Results Conference Call on March 25 at 8:30 a.m. Eastern Time

    MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the fourth quarter and year ended December 31, 2018 at 8:30 am Eastern Time on Monday, March 25, 2019. Following the release, MediWound's management will host a conference call for the investment community beginning at 8:30 a.m. Eastern Time to discuss the financial results and to answer questions. Shareholders and other interested parties may participate in the conference call by dialing 877-602-7189 (in the U.S.), 1809 315 362 (Israel), or 678-894-3057 (outside the U.S. & Israel) and entering passcode 2997019.

  • GlobeNewswire4 months ago

    MediWound Announces Executive Leadership Changes

    MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Chief Executive Officer, Gal Cohen, has decided to step down after serving as the Company’s CEO for more than 12 years. Mr. Cohen will end his term by the end of May 2019 and during this period, continue to support the Company’s transition and ongoing strategic process. Sharon Malka, the Company’s Chief Financial Officer and Chief Operations Officer, will be appointed CEO, and Stephen T. Wills, the Company’s Chairman of the Board of Directors, will serve as Active Chairman.

  • Earnings Preview: MediWound (MDWD) Q4 Earnings Expected to Decline
    Zacks4 months ago

    Earnings Preview: MediWound (MDWD) Q4 Earnings Expected to Decline

    MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Do Institutions Own MediWound Ltd. (NASDAQ:MDWD) Shares?
    Simply Wall St.5 months ago

    Do Institutions Own MediWound Ltd. (NASDAQ:MDWD) Shares?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you want to know who reallyRead More...

  • ACCESSWIRE6 months ago

    4 Healthcare Stocks Looking to Set the Pace on Tuesday (1/22/19)

    With the rise of global population, coupled with depletion of most common resources, consumer access to healthcare is crucial to securing the health and wellness of all living people, resulting in a need for companies in the space to meet these demands. Premier Health Group (OTC:PHGRF) (CSE:PHGI), MediWound Ltd (MDWD), Neovasc Inc (NVCN), and Teladoc Health Inc (TDOC) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients. Premier Health Group (OTC:PHGRF) (CSE:PHGI) has enjoyed impressive gains over the last three weeks as the company has taken strides to make key investments in the cannabis industry, allowing for the integration of new approaches to treatment options for their patients.

  • GlobeNewswire6 months ago

    MediWound Announces Positive Top-Line Results from Its Pivotal Phase 3 Study (DETECT) in NexoBrid® for Eschar Removal of Severe Thermal Burns

    MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it has met its primary and all secondary endpoints in its pivotal U.S. Phase 3 clinical study (DETECT) with NexoBrid to treat patients with deep partial thickness (DPT) and full thickness (FT) thermal burns intended for submission for Biological License Application (BLA) from U.S. Food and Drug Administration (FDA). “We are thrilled to announce these robust positive results across all endpoints, which corroborate our previous positive EU Phase 3 clinical study results and clearly demonstrate the significant beneficial impact NexoBrid has on patients’ lives,” said Gal Cohen, President and Chief Executive Officer of MediWound.

  • ACCESSWIRE6 months ago

    MediWound’s Late Stage Clinical Products Review, Analysts Review and Target

    NEW YORK, NY / ACCESSWIRE / January7, 2019 / Traders News Source, a leading independent equity researchand corporate access firm focused on small and mid-cap public companies isissuing a comprehensive report on MediWound Ltd. (NASDAQ: MDWD), a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound's first biopharmaceutical product, NexoBrid®, received marketing authorization from the European Medicines Agency as well as the Israeli, Argentinian, South Korean and Russian Ministries of Health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns.